Compare PGC & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PGC | CMPS |
|---|---|---|
| Founded | 1921 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 698.4M | 724.5M |
| IPO Year | 1997 | 2020 |
| Metric | PGC | CMPS |
|---|---|---|
| Price | $39.38 | $9.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $40.50 | $26.57 |
| AVG Volume (30 Days) | 103.5K | ★ 4.3M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.50% | N/A |
| EPS Growth | ★ 13.51 | N/A |
| EPS | ★ 2.10 | N/A |
| Revenue | ★ $282,995,000.00 | N/A |
| Revenue This Year | $32.39 | N/A |
| Revenue Next Year | $12.64 | N/A |
| P/E Ratio | $19.00 | ★ N/A |
| Revenue Growth | ★ 24.05 | N/A |
| 52 Week Low | $24.45 | $2.25 |
| 52 Week High | $40.41 | $10.21 |
| Indicator | PGC | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 65.11 | 74.48 |
| Support Level | $32.44 | $4.56 |
| Resistance Level | $40.41 | N/A |
| Average True Range (ATR) | 1.03 | 0.63 |
| MACD | 0.04 | 0.44 |
| Stochastic Oscillator | 78.23 | 84.90 |
Peapack Gladstone Financial Corp is a bank holding company. Through its subsidiaries, the company offers various wealth management, investment banking, and commercial and personal banking solutions to its clients. The company has two reportable segments: Banking, which generates the maximum revenue, and Wealth Management. The Banking segment includes commercial, commercial real estate, multifamily, residential, and consumer lending activities; treasury management services; escrow management; deposit generation; operation of ATMs; telephone and internet banking services; credit card services, etc. The Wealth Management segment offers investment management services for individuals and institutions; personal trust services; and other financial planning and advisory services.
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.